Improved effects of Budesonide/Formoterol combination therapy (Symbicort) on the residual eosinophilic inflammation in the distal airways of asthmatic patients who used the salmeterol/fluticasone combination drug

Improved effects of Budesonide/Formoterol combination therapy (Symbicort) on the residual eosinophilic inflammation in the distal airways of asthmatic patients who used the salmeterol/fluticasone combination drug - Effects of Budesonide/Formoterol combination therapy (Symbicort) on the distal airway inflammation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003805

Enrollment

Registered

2010-06-24

Start date

2010-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial asthma

Interventions

We evaluate the improved effects of Symbicort on the residual airway inflammation in the distal airway of the well-controlled asthmatic patients who used salmeterol/fluticasone combination drug.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who regularly used salmeterol/fluticasone combination drug more than 3 months. 2. Stable well-controlled asthmatic patients

Exclusion criteria

Exclusion criteria: 1. Past history of asthma attach in the previous 3 months. 2. Past treatments with oral corticosteroids in the previous 2 weeks. 3. Chronic obstructive lung disease (COPD) and other respiratory disease. 4. Severe liver, kidney, heart, hematic and other diseases 5. Inappropriate patients from the doctor's viewpoint

Design outcomes

Primary

Measure	Time frame
distal airway inflammation in induced sputum (Eosinophil counts, ECP and SPD)	—

Secondary

Measure	Time frame
Asthma related QOL(AQLQ), impulse oscillometry system (IOS), FeNO, Pulmonary function test, Eosinophils in peripheral blood	—

Countries

Japan

Contacts

Public ContactHiroyuki Ohbayashi

JA Tohno Kousei Hospital Allergy and Respiratory Medicine

ohbayasi@nn.iij4u.or.jp0572-68-4111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026